Dinutuximab Clinical Trials

4 actively recruiting trials across 3 locations

Also known as: Ch 14.18UTC, Ch14.18, Dinutuximab Beta, MOAB Ch14.18, Qarziba +2 more

Pipeline

Phase 2: 1Phase 3: 2Phase 1/2: 1

Top Sponsors

New Approaches to Neuroblastoma Therapy Consortium1
Nationwide Children's Hospital1
National Cancer Institute (NCI)1
Children's Oncology Group1

Indications

Cancer4
Neuroblastoma3
Ganglioneuroblastoma, Nodular2
Ganglioneuroblastoma1
Refractory Neuroblastoma1

Birmingham, Alabama2 trials

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

Children's Hospital of Alabama

Phase 3

Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

Children's Hospital of Alabama

Phase 3

Los Angeles, California1 trial

NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial

Children's Hospital Los Angeles

Phase 2

Columbus, Ohio1 trial

NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab

Nationwide Children's Hospital

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.